Aquestive Therapeutics, Inc. AQST Sales of Royalty Rights
Sales of Royalty Rights at other companies
Other financials
Where this comes from
Reported directly by Aquestive Therapeutics, Inc. in its filing.
Tagged under the XBRL concept aqst:DeferredTaxAssetRoyaltyObligations.
The official record: Aquestive Therapeutics, Inc.’s 10-K, filed March 4, 2026, on SEC EDGAR. View the filing →
Ask your AI about Aquestive Therapeutics, Inc.'s sales of royalty rights.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Aquestive Therapeutics, Inc.'s sales of royalty rights?
- Aquestive Therapeutics, Inc. (AQST) reported sales of royalty rights of $5.06M in Q4 2025.
- What is the long-term trend for Aquestive Therapeutics, Inc.'s sales of royalty rights?
- Over 2 years (2023 to 2025), Aquestive Therapeutics, Inc.'s sales of royalty rights has grown at a 19.8% compound annual growth rate (CAGR), from $3.52M to $5.06M.
- What does sales of royalty rights mean?
- This represents deferred tax assets related to obligations arising from the sale or licensing of royalty rights. It reflects the timing differences between the recognition of royalty income for financial reporting and the tax treatment of the associated obligations. Understanding this metric helps in assessing the long-term tax liabilities and cash flow impacts of the company's licensing business model.